Neurocrine Biosciences, Inc. (NBIX) Latest Company News

Aug 26, 2026, 11:00 UTC
Neurocrine Biosciences' IND for NBI-1117567 Phase 2 trial in Alzheimer's cognitive impairment was accepted by the US FDA, triggering a $10 million milestone payment to Nexera Pharma.
Source:
Aug 22, 2026, 07:07 UTC
Allworth Financial LP acquired a new position in Neurocrine Biosciences, Inc., purchasing 14,853 shares valued at approximately $2.50 million, as disclosed in a recent SEC filing.
Source:
- defenseworld.net
Aug 12, 2026, 15:57 UTC
Neurocrine Biosciences Inc. stock fell almost 5% on Wednesday before recovering after physicians and experts in Prader-Willi syndrome notified clinicians of some cases of deaths and severe complications potentially associated with Vykat XR (diazoxide choline).
Source:
- benzinga.com
Aug 12, 2026, 12:30 UTC
Neurocrine Biosciences announced the publication of KINECT-PRO Phase 4 study results showing INGREZZA (valbenazine) improved quality of life and daily functioning in patients with tardive dyskinesia.
Source:
- prnewswire.com
Jul 30, 2026, 20:01 UTC
Neurocrine Biosciences reported second-quarter 2026 financial results with total revenue of $959 million, up 39% year-over-year, and raised its 2026 INGREZZA net sales guidance to $2.825-$2.875 billion.
Source:
Jul 23, 2026, 20:05 UTC
Neurocrine Biosciences announced the appointment of three Senior Vice Presidents to strengthen its leadership team.
Source:
- prnewswire.com
Jun 15, 2026, 12:30 UTC
Neurocrine Biosciences presented new two-year data for its drug CRENESSITY (crinecerfont) at the ENDO 2026 conference, showing improvements in cardiometabolic outcomes in adults with classic congenital adrenal hyperplasia.

NBIX

Neurocrine Biosciences' IND for NBI-1117567 Phase 2 trial in Alzheimer's cognitive impairment was accepted by the US FDA, triggering a $10 million milestone payment to Nexera Pharma.

Allworth Financial LP acquired a new position in Neurocrine Biosciences, Inc., purchasing 14,853 shares valued at approximately $2.50 million, as disclosed in a recent SEC filing.

Neurocrine Biosciences Inc. stock fell almost 5% on Wednesday before recovering after physicians and experts in Prader-Willi syndrome notified clinicians of some cases of deaths and severe complications potentially associated with Vykat XR (diazoxide choline).

Neurocrine Biosciences announced the publication of KINECT-PRO Phase 4 study results showing INGREZZA (valbenazine) improved quality of life and daily functioning in patients with tardive dyskinesia.

Neurocrine Biosciences reported second-quarter 2026 financial results with total revenue of $959 million, up 39% year-over-year, and raised its 2026 INGREZZA net sales guidance to $2.825-$2.875 billion.

Neurocrine Biosciences announced the appointment of three Senior Vice Presidents to strengthen its leadership team.

Neurocrine Biosciences presented new two-year data for its drug CRENESSITY (crinecerfont) at the ENDO 2026 conference, showing improvements in cardiometabolic outcomes in adults with classic congenital adrenal hyperplasia.